Overview: Parkinson’s disease is one of the most prevalent neurodegenerative disorders, which progresses with age because of damaged dopaminergic cells in the brain. Bradykinesia, rigidity, postural instability, and tremors are the symptoms of the Parkinson’s disease. Huge patient pool and rising rate of diagnosis are the significant factors driving the market growth. The Parkinson’s disease Foundation has stated that nearly 10 million people are suffering from this disorder globally. The highest frequency of this disorder is observed in developed countries, and in the US, almost 60,000 new cases are reported annually.
Market Analysis: The “Global Parkinson’s Disease Drugs Market” is estimated to witness a CAGR of 7.2% during the forecast period 2018–2024. The market is analyzed based on two segments – drug class and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America accounts for the largest share of the market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by Europe, with Germany being the major contributor to the market growth.
Get Sample Copy of this
https://healthcareintelligencemarkets.com/request_sample.php?id=58
Key Players: The major players in the market include Novartis, Roche, AbbVie, Teva Pharmaceutical, Pfizer, STADA Arzneimittel AG, GSK, Valeant, Merck & Co. Inc., and Amneal Pharmaceuticals Inc.
Drug Class Analysis: Drug Class Analysis: Based on drug classes, the market is segmented into levodopa, MAO-B inhibitors, COMT inhibitors, dopamine agonists, anticholinergics, and others. Levodopa is the most attractive drug in the market owing to its highly effective treatment in controlling the motor symptoms throughout the stages of Parkinson’s disease. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa. This is the original drug indicated explicitly for dyskinesia, which is technologically advanced with the long-term use of levodopa.
Competitive Analysis: New product launch and collaboration are the primary strategies being followed by the market players to maintain their leadership and strengthen the market position. In January 2015, Neuropore Therapies Inc. and UCB S.A. signed a commercialization agreement for NPT200-11. Recently, Impax Pharmaceuticals’ RYTARY and AbbVie’s DUOPA received the US FDA approval for the treatment of Parkinson’s disease. Other strategies include business partnerships, mergers & acquisitions, and a multifaceted pipeline. Recently, in January 2018, Adamas Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in individuals with PD, who are taking levodopa.
Get Reasonable Discount on this Premium Report @: https://healthcareintelligencemarkets.com/ask_for_discount.php?id=58
Key questions answered through this research report:
What will the growth rate and market size in the market forecast period?
Which factors are responsible for driving the global market?
What are the challenges in front of the global market?
What are the global market opportunities for expanding businesses?
What are the key outcomes of industry analysis techniques?
Who are the key vendors of the global Parkinson’s Disease Drugs market?
What are the trending factors influencing on the global market?
Benefits: The report provides complete details about the usage and adoption rate of Parkinson’s disease drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
For More Information: https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=58
Reasons for buying this report?
It provide an analysis of changing competitive scenario.
For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.
It offers 2026 year assessment of global Parkinson’s Disease Drugs sector.
It helps in understanding the major key product segments such as Parkinson’s Disease Drugs.
Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.
It offers regional analysis of global Parkinson’s Disease Drugs industries along with business profiles of several stakeholders.
It offers massive data about trending factors that will influence the progress of the Parkinson’s Disease Drugs market.
If you have any special requirements, please let us know and we will provide you the report as you want.
About Us:
At HealthCare Intelligence Markets
Contact Us:
Address: 90, State Office Center,
90, State Street Suite 700,
Albany, NY 12207
Email: sales@healthcareintelligencemarkets.com
Web: www.healthcareintelligencemarkets.com
Phone: +1 (888) 616-2766
Here’s How Parkinson’s disease Drugs Market 2019
